SK Plasma said that it had signed a contract to export 17.2 billion won ($14.2 million) worth of blood products with Aksia Health Care FZC.Products for export included LIV-r Inj. and albumin.Under the accord, Aksia will have the right to sell the product in Saudi Arabia, Kuwait, and the United Arab
Samsung Bioepis and Organon said that the U.S. Food and Drug Administration (FDA) had accepted for review their supplemental Biologics License Application (sBLA) for a citrate-free, high-concentration formulation of SB5, a Humira (Adalimumab) biosimilar.SB5 also received approval from the FDA under
Celltrion said that Health Canada, which authorizes medicinal products, has granted sales approval to Yuflyma, a new biosimilar of Abbvie's blockbuster drug, Humira (Ingredient: Adalimumab).The company has gained approval for Humira's indications, including rheumatoid arthritis, inflammatory bowel d
AbClon has received regulatory approval to conduct phase 1 and 2 clinical trials of AT101, a CAR-T therapy with new antibodies, for blood cancer patients.AT101 is a CAR-T immuno-oncology that targets the CD19 protein, and its application area is completely different from the existing global blockbus
Kolon TissueGene said it has resumed administering Invossa (TG-C), cell-mediated gene therapy for osteoarthritis, in phase 3 clinical trials for knee osteoarthritis in the United States.The medication began in Source Healthcare in Santa Monica, Calif. The company plans to complete the trials of Invo
LegoChem Biosciences has signed a co-development and technology transfer agreement with the U.K. Iksuda Therapeutics for LCB14, an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) undergoing studies in China.Under the accord, Iksuda gained exclusive rights for
EuBiologics said it signed an MOU with Arabio, a Saudi Arabian biotech firm, to supply its Covid-19 vaccine EuCorVac-19 and meningococcal vaccine Eu-MCV to Saudi Arabia.Arabio is a major biopharmaceutical firm in six countries of the Gulf Cooperation Council (GCC). It partners with multinational pha
Enzychem Lifesciences recently corrected its registration statement to mention risks in Covid-19 vaccine manufacturing before a bonus issue, arousing questions about whether the vaccine manufacturing will be a boon for the company.The biotech company hopes that making an Indian drugmaker’s Covid-19
Biogen said it would slash the price of Aduhelm (aducanumab), an anti-amyloid beta antibody treatment to treat Alzheimer’s disease, and possibly carry out layoffs in return.On Monday, the drugmaker said that it would reduce the wholesale price of Aduhelm 100mg/mL by 50 percent, effective Jan. 1, 202
HLB said it has verified the safety and protection of the Covid-19 vaccine, Nanocovax, developed by Vietnam-based pharmaceutical company, Nanogen. The Vietnamese Ministry of Health said that the protective effect of Nanocovax exceeded 50 percent of the minimum standard suggested by the World Health
M2N, the largest stakeholder of Sillajen, has been freed from a creditor’s attempt to file a bankruptcy.On Thursday, M2N said a court dismissed the bankruptcy application in public disclosure.According to M2N, the Seoul Bankruptcy Court rejected the bankruptcy application filed by Seed Nine Partners
Moderna’s Covid-19 vaccines manufactured by Samsung Biologics have been released for the Korean market for the first time.The Ministry of Food and Drug Safety said on Thursday it granted lot release approval for Moderna’s Covid-19 vaccine Spikevax Inj. produced by Samsung Biologics.On Monday, Modern
Prestige Biopharma said that Dr. Reddy's Laboratories would market Tuznue, its Herceptin biosimilar, in South America and Southeast Asia.Under the accord, Prestige Biopharma will entrust Dr. Reddy's Laboratories with exclusive commercialization rights for Tuznue in eight countries -- five in South A
Samsung Bioepis said Thursday that SB3, a biosimilar of Herceptin (ingredient: trastuzumab), showed similar long-term survival results to its original drug after a median follow-up of 68 months from the phase 3 study.The five-year results are the longest monitored data as of December 2021 for a tras
Major multinational pharmaceutical companies are expected to attend the annual J.P. Morgan Healthcare Conference in San Francisco, CA., in the U.S. in January, drawing attention to whether Korean biotech companies will join the event.As the upcoming conference will be held face to face, Korean compa
The continued spread of the new Omicron variant has prompted Korean vaccine makers to review whether to develop Omicron-targeted Covid-19 vaccines.Industry sources said Eyegene, mCureX Therapeutics, and Eubiologics are mulling developing a new Omicron-specific vaccine or a polyvalent vaccine.On Wedn
Samsung Bioepis will be unable to sell Eticovo, a biosimilar of autoimmune disease treatment, Enbrel (Ingredient: etanercept), in the U.S. until 2029 as the company lost a patent lawsuit with its developer Immunex.According to industry insiders, the New Jersey district court ruled in favor of Amgen,
Big Pharma is finding it hard to keep up with challenges from biosimilar makers, including Korean companies, rapidly penetrating the global market dominated by original drugs, industry watchers said Friday.The rheumatoid arthritis treatment market is a case in point, where originals’ sales have cont
BIOnSYSTEMS’ new immunotherapy candidate BNS001 has been selected for government support for the second national new drug development project in 2021, the company said Wednesday.BNS001 is a dual-function protein immunotherapy candidate, in which “mutant-type Fc” with better durability in the blood i
TiumBio is working on various pipelines, including an anticancer drug inhibiting both TGF-β and VEGFR-2, an endometriosis drug, and hemophilia treatment.The market’s expectation for TiumBio is increasing because global trials of the company’s experimental drugs are expected to progress swiftly.Monda